Minimizing the risk of reporting false positives in large-scale RNAi screens

被引：336

作者：

Echeverri, Christophe J.

Beachy, Philip A.

Baum, Buzz

Boutros, Michael

Buchholz, Frank

Chanda, Sumit K.

Downward, Julian

Ellenberg, Jan

Fraser, Andrew G.

Hacohen, Nir

Hahn, William C.

Jackson, Aimee L.

Kiger, Amy

Linsley, Peter S.

Lum, Lawrence

Ma, Yong

Mathey-Prevot, Bernard

Root, David E.

Sabatini, David M.

Taipale, Jussi

Perrimon, Norbert

Bernards, Rene

机构：

[1] Cenix BioSci GMBH, D-10307 Dresden, Germany

[2] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA

[3] Ludwig Inst Canc Res, Morhpogenesis Grp, UCL Branch, London W1W 7BS, England

[4] German Canc Res Ctr, Signalling & Funct Genom, D-69120 Heidelberg, Germany

[5] Max Planck Inst Mol Cell Biol & Genet, D-10307 Dresden, Germany

[6] Novartis Res Fdn, Febim Inst, Div Cellular Genom, San Diego, CA 92121 USA

[7] Canc Res UK, London Res Inst, London WC2A 3PX, England

[8] European Mol Biol Lab, Gene Express Unit, D-69117 Heidelberg, Germany

[9] Wellcome Trust Sanger Inst, Cambridge CB10 1HH, England

[10] MIT, Broad Inst, Cambridge, MA 02142 USA

[11] Harvard Univ, Cambridge, MA 02142 USA

[12] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA

[13] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[14] Rosetta Inpharm, Seattle, WA 98109 USA

[15] Univ Calif San Diego, Dept Cell & Dev Biol, La Jolla, CA 92093 USA

[16] Univ Texas, Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA

[17] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA

[18] Harvard Univ, Sch Med, Drosophilia RNAi Screening Ctr, Boston, MA 02115 USA

[19] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA

[20] Univ Helsinki, Biomedicum, Mol & Canc Biol Program, FIN-00014 Helsinki, Finland

[21] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA

[22] Netherlands Canc Inst, Div Mol Carcinogenesis, NL-1066 CX Amsterdam, Netherlands

[23] Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands

来源：

NATURE METHODS | 2006年 / 3卷 / 10期

关键词：

D O I：

10.1038/nmeth1006-777

中图分类号：

Q5 [生物化学];

学科分类号：

071010 ; 081704 ;

摘要：

Large-scale RNA interference (RNAi)-based analyses, very much as other 'omic' approaches, have inherent rates of false positives and negatives. The variability in the standards of care applied to validate results from these studies, if left unchecked, could eventually begin to undermine the credibility of RNAi as a powerful functional approach. This Commentary is an invitation to an open discussion started among various users of RNAi to set forth accepted standards that would insure the quality and accuracy of information in the large datasets coming out of genome-scale screens.

引用

页码：777 / 779

页数：3

共 7 条

[1] 3′ UTR seed matches, but not overall identity, are associated with RNAi off-targets [J].